Abstract
High-throughput screening (HTS) assays enable the testing of large numbers of chemical substances for activity in diverse areas of biology. The biological responses measured in HTS assays span isolated biochemical systems containing purified receptors or enzymes to signal transduction pathways and complex networks functioning in cellular environments. This Review addresses factors that need to be considered when implementing assays for HTS and is aimed particularly at investigators new to this field. We discuss assay design strategies, the major detection technologies and examples of HTS assays for common target classes, cellular pathways and simple cellular phenotypes. We conclude with special considerations for configuring sensitive, robust, informative and economically feasible HTS assays.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zhang, R. et al. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 270, 268–275 (1999).
McDonald, O.B. et al. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal. Biochem. 268, 318–329 (1999).
Seville, M., West, A.B., Cull, M.G. & McHenry, C.S. Fluorometric assay for DNA polymerases and reverse transcriptase. Biotechniques 21, 664–672 (1996).
Verma, R. et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117–120 (2004).
Ferrer, M. et al. A fully automated [35S]GTPgammaS scintillation proximity assay for the high-throughput screening of Gi-linked G protein-coupled receptors. Assay Drug Dev. Technol. 1, 261–273 (2003).
Dinger, M.C. & Beck-Sickinger, A.G. in Molecular Biology in Medicinal Chemistry (eds. Dingermann, T., Steinhiber, D. & Folkers, G.) 73–94 (Wiley-VCH Verlag GmbH & Co., Weinheim, Germany, 2004).
Hodder, P., Mull, R., Cassaday, J., Berry, K. & Strulovici, B. Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader. J. Biomol. Screen. 9, 417–426 (2004).
Inglese, J. (ed.) Measuring Biological Responses with Automated Microscopy Vol. 414 (Elsevier Academic, San Diego, 2006).
Taylor, D.L., Haskins, J.R. & Giuliano, K.A. (eds.) High Content Screening Vol. 356 (Humana, Totowa, New Jersey, 2006).
Sever, J.L. Application of a microtechnique to viral serological investigations. J. Immunol. 88, 320–329 (1962).
Carroll, S.S., Inglese, J., Mao, S.-S. & Olsen, D.B. in Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development (ed. Prendergast, G.C.) 119–140 (John Wiley & Sons, Inc., Hoboken, New Jersey, USA, 2004).
Wölcke, J. & Ullmann, D. Miniaturized HTS technologies - uHTS. Drug Discov. Today 6, 637–646 (2001).
Karvinen, J. et al. Caspase multiplexing: simultaneous homogeneous time-resolved quenching assay (TruPoint) for caspases 1, 3, and 6. Anal. Biochem. 325, 317–325 (2004).
Bandyopadhyay, S. et al. A high-throughput drug screen targeted to the 5′untranslated region of Alzheimer amyloid precursor protein mRNA. J. Biomol. Screen. 11, 469–480 (2006).
Davis, R.E. et al. A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. Assay Drug Dev. Technol. 5, 85–104 (2007).
O'Boyle, D.R. II et al. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49, 1346–1353 (2005).
Ross, S. et al. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays. Assay Drug Dev. Technol. 4, 397–409 (2006).
Iversen, P.W., Eastwood, B.J., Sittampalam, G.S. & Cox, K.L. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. J. Biomol. Screen. 11, 247–252 (2006).
Eastwood, B.J. et al. The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. J. Biomol. Screen. 11, 253–261 (2006).
Assay Guidance Manual Committee. Assay Guidance Manual Version 4.1 (Eli Lilly and Company and NIH Chemical Genomics Center, Bethesda, Maryland, 2005).
Fluorescence Spectra Viewer (Invitrogen Corporation, Carlsbad, California, 2006). <http://probes.invitrogen.com/servlets/spectraviewer?fileid1=1304dna>
Lakowicz, J.R. Principles of Fluorescence Spectroscopy (Springer, Berlin, 2006).
Owicki, J.C. Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J. Biomol. Screen. 5, 297–306 (2000).
Jameson, D.M. & Croney, J.C. Fluorescence polarization: past, present and future. Comb. Chem. High Throughput Screen. 6, 167–176 (2003).
Hemmila, I. & Laitala, V. Progress in lanthanides as luminescent probes. J. Fluoresc. 15, 529–542 (2005).
Trinquet, E. & Mathis, G. Fluorescence technologies for the investigation of chemical libraries. Mol. Biosyst. 2, 380–387 (2006).
Giepmans, B.N., Adams, S.R., Ellisman, M.H. & Tsien, R.Y. The fluorescent toolbox for assessing protein location and function. Science 312, 217–224 (2006).
Haugland, R.P. The Handbook—A Guide to Fluorescent Probes and Labeling Technologies 10th edn. (Eugene, Oregon, 2006).
Medintz, I.L., Uyeda, H.T., Goldman, E.R. & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4, 435–446 (2005).
Haney, S.A., LaPan, P., Pan, J. & Zhang, J. High-content screening moves to the front of the line. Drug Discov. Today 11, 889–894 (2006).
Bowen, W.P. & Wylie, P.G. Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev. Technol. 4, 209–221 (2006).
Fan, F. & Wood, K.V. Bioluminescent assays for high-throughput screening. Assay Drug Dev. Technol. 5, 127–136 (2007).
Nakatsu, T. et al. Structural basis for the spectral difference in luciferase bioluminescence. Nature 440, 372–376 (2006).
Blair, W.S. et al. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Res. 65, 107–116 (2005).
Hao, W. et al. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 51, 95–102 (2007).
Zlokarnik, G. Fusions to beta-lactamase as a reporter for gene expression in live mammalian cells. Methods Enzymol. 326, 221–244 (2000).
Kunapuli, P. et al. Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal. Biochem. 314, 16–29 (2003).
Oosterom, J., van Doornmalen, E.J., Lobregt, S., Blomenrohr, M. & Zaman, G.J. High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. Assay Drug Dev. Technol. 3, 143–154 (2005).
Pfleger, K.D. & Eidne, K.A. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat. Methods 3, 165–174 (2006).
Remy, I. & Michnick, S.W. Mapping biochemical networks with protein-fragment complementation assays. Methods Mol. Biol. 261, 411–426 (2004).
Wu, S. & Liu, B. Application of scintillation proximity assay in drug discovery. BioDrugs 19, 383–392 (2005).
Lavery, P., Brown, M.J. & Pope, A.J. Simple absorbance-based assays for ultra-high throughput screening. J. Biomol. Screen. 6, 3–9 (2001).
Zuck, P. et al. Miniaturization of absorbance assays using the fluorescent properties of white microplates. Anal. Biochem. 342, 254–259 (2005).
Zheng, C.J. et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol. Rev. 58, 259–279 (2006).
Fox, S. et al. High-throughput screening: update on practices and success. J. Biomol. Screen. 11, 864–869 (2006).
Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 (2002).
Pawson, T. & Scott, J.D. Protein phosphorylation in signaling—50 years and counting. Trends Biochem. Sci. 30, 286–290 (2005).
Singh, P., Harden, B.J., Lillywhite, B.J. & Broad, P.M. Identification of kinase inhibitors by an ATP depletion method. Assay Drug Dev. Technol. 2, 161–169 (2004).
Munagala, N. et al. Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay. Assay Drug Dev. Technol. 5, 65–73 (2007).
Lowery, R.G. & Kleman-Leyer, K. Transcreener: screening enzymes involved in covalent regulation. Expert Opin. Ther. Targets 10, 179–190 (2006).
Charter, N.W., Kauffman, L., Singh, R. & Eglen, R.M. A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5′-diphosphate accumulation. J. Biomol. Screen. 11, 390–399 (2006).
Sportsman, J.R., Gaudet, E.A. & Boge, A. Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev. Technol. 2, 205–214 (2004).
Comley, J. Kinase screening and profiling-spoilt for choice. Drug Discov. World 7, 27–50 (2006).
Morgan, A.G., McCauley, T.J., Stanaitis, M.L., Mathrubutham, M. & Millis, S.Z. Development and validation of a fluorescence technology for both primary and secondary screening of kinases that facilitates compound selectivity and site-specific inhibitor determination. Assay Drug Dev. Technol. 2, 171–181 (2004).
Newbatt, Y. et al. Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. J. Biomol. Screen. 11, 145–154 (2006).
Osmond, R.I. et al. GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J. Biomol. Screen. 10, 730–737 (2005).
Eglen, R.M. & Singh, R. Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening. Comb. Chem. High Throughput Screen. 6, 381–387 (2003).
Zaman, G.J., van der Lee, M.M., Kok, J.J., Nelissen, R.L. & Loomans, E.E. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors. Assay Drug Dev. Technol. 4, 411–420 (2006).
Barnett, S.F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399–408 (2005).
Leung, D., Abbenante, G. & Fairlie, D.P. Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305–341 (2000).
Grant, S.K., Sklar, J.G. & Cummings, R.T. Development of novel assays for proteolytic enzymes using rhodamine-based fluorogenic substrates. J. Biomol. Screen. 7, 531–540 (2002).
Auld, D. in Proteolytic Enzymes Tools: and Targets (eds. Stocker, W. & Sterchi, E. E.) 30–48 (Springer-Velag, Berlin Heidelberg, 1999).
Ferrer, M. et al. Miniaturizable homogenous time-resolved fluorescence assay for carboxypeptidase B activity. Anal. Biochem. 317, 94–98 (2003).
Jones, J., Heim, R., Hare, E., Stack, J. & Pollok, B.A. Development and application of a GFP-FRET intracellular caspase assay for drug screening. J. Biomol. Screen. 5, 307–317 (2000).
Whitney, M. et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. J. Biomol. Screen. 7, 149–154 (2002).
Lee, J.C. et al. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316, 162–170 (2003).
Li, Y., Liu, Y.W. & Cordell, B. Novel functional assay for proteases and modulators. Application in beta-secretase studies. Mol. Biotechnol. 18, 1–10 (2001).
Olefsky, J.M. Nuclear receptor minireview series. J. Biol. Chem. 276, 36863–36864 (2001).
Zeh, K. et al. Gain-of-function somatic cell lines for drug discovery applications generated by homologous recombination. Assay Drug Dev. Technol. 1, 755–765 (2003).
Sun, S., Almaden, J., Carlson, T.J., Barker, J. & Gehring, M.R. Assay development and data analysis of receptor-ligand binding based on scintillation proximity assay. Metab. Eng. 7, 38–44 (2005).
Parker, G.J., Law, T.L., Lenoch, F.J. & Bolger, R.E. Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J. Biomol. Screen. 5, 77–88 (2000).
Fung, P. et al. A homogeneous cell-based assay to measure nuclear translocation using beta-galactosidase enzyme fragment complementation. Assay Drug Dev. Technol. 4, 263–272 (2006).
Mackem, S., Baumann, C.T. & Hager, G.L. A glucocorticoid/retinoic acid receptor chimera that displays cytoplasmic/nuclear translocation in response to retinoic acid. A real time sensing assay for nuclear receptor ligands. J. Biol. Chem. 276, 45501–45504 (2001).
Wehrman, T.S., Casipit, C.L., Gewertz, N.M. & Blau, H.M. Enzymatic detection of protein translocation. Nat. Methods 2, 521–527 (2005).
Gowda, K., Marks, B.D., Zielinski, T.K. & Ozers, M.S. Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-gamma using time-resolved fluorescence resonance energy transfer. Anal. Biochem. 357, 105–115 (2006).
Zhu, Z. et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J. Biomol. Screen. 9, 533–540 (2004).
Eglen, R.M., Bosse, R. & Reisine, T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throghput screening. Assay Drug Dev. Technol. 5, 425–451 (2007).
Jacoby, E., Bouhelal, R., Gerspacher, M. & Seuwen, K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 1, 761–782 (2006).
Yu, N. et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal. Chem. 78, 35–43 (2006).
Handl, H.L. & Gillies, R.J. Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci. 77, 361–371 (2005).
Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15, 598–611 (2001).
Behan, D.P. & Chalmers, D.T. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr. Opin. Drug Discov. Devel. 4, 548–560 (2001).
Labrecque, J. et al. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev. Technol. 3, 637–648 (2005).
Chambers, C. et al. Measuring intracellular calcium fluxes in high throughput mode. Comb. Chem. High Throughput Screen. 6, 355–362 (2003).
Williams, C. cAMP detection methods in HTS: selecting the best from the rest. Nat. Rev. Drug Discov. 3, 125–135 (2004).
Reinscheid, R.K., Kim, J., Zeng, J. & Civelli, O. High-throughput real-time monitoring of Gs-coupled receptor activation in intact cells using cyclic nucleotide-gated channels. Eur. J. Pharmacol. 478, 27–34 (2003).
Adie, E.J. et al. CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells. Assay Drug Dev. Technol. 1, 251–259 (2003).
Charest, P.G., Terrillon, S. & Bouvier, M. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep. 6, 334–340 (2005).
Karlsson, A.M. et al. Biosensing of opioids using frog melanophores. Biosens. Bioelectron. 17, 331–335 (2002).
Burstein, E.S. et al. Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout. Curr. Pharm. Des. 12, 1717–1729 (2006).
Liu, A.M. et al. Galpha(16/z) chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization. J. Biomol. Screen. 8, 39–49 (2003).
Kostenis, E. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol. Sci. 22, 560–564 (2001).
Trinquet, E. et al. D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal. Biochem. 358, 126–135 (2006).
Hamdan, F.F., Audet, M., Garneau, P., Pelletier, J. & Bouvier, M. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J. Biomol. Screen. 10, 463–475 (2005).
Zheng, W., Spencer, R.H. & Kiss, L. High throughput assay technologies for ion channel drug discovery. Assay Drug Dev. Technol. 2, 543–552 (2004).
McDonough, S.I. & Bean, B.P. in Voltage-Gated Ion Channels as Drug Targets Vol. 29 (eds. Triggle, D.J., Gopalakrishnan, M., Rampe, D. & Zheng, W.) 19–35 (Wiley-VCH, Weinheim, Germany, 2006).
Gee, K.R. et al. Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 27, 97–106 (2000).
Gonzalez, J.E. & Maher, M.P. Cellular fluorescent indicators and voltage/ion probe reader (VIPR) tools for ion channel and receptor drug discovery. Receptors Channels 8, 283–295 (2002).
Terstappen, G.C. Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev. Technol. 2, 553–559 (2004).
Finkel, A. et al. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J. Biomol. Screen. 11, 488–496 (2006).
Wible, B.A. et al. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136–145 (2005).
Schwab, D., Fischer, H., Tabatabaei, A., Poli, S. & Huwyler, J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. 46, 1716–1725 (2003).
Henrich, C.J. et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen. 11, 176–183 (2006).
Wieczorke, R., Dlugai, S., Krampe, S. & Boles, E. Characterisation of mammalian GLUT glucose transporters in a heterologous yeast expression system. Cell. Physiol. Biochem. 13, 123–134 (2003).
Verkman, A.S. Drug discovery in academia. Am. J. Physiol. Cell Physiol. 286, C465–C474 (2004).
Rubin, L.L. & de Sauvage, F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5, 1026–1033 (2006).
Massoud, T.F., Paulmurugan, R., De, A., Ray, P. & Gambhir, S.S. Reporter gene imaging of protein-protein interactions in living subjects. Curr. Opin. Biotechnol. 18, 31–37 (2007).
MacDonald, M.L. et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2, 329–337 (2006).
Buttner, F.H., Kumpf, R., Menzel, S., Reulle, D. & Valler, M.J. Evaluation of the InteraX system technology in a high-throughput screening environment. J. Biomol. Screen. 10, 485–494 (2005).
Wallrabe, H. & Periasamy, A. Imaging protein molecules using FRET and FLIM microscopy. Curr. Opin. Biotechnol. 16, 19–27 (2005).
Marine, S. et al. A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation. Anal. Biochem. 355, 267–277 (2006).
Wolff, M. et al. Automated high content screening for phosphoinositide 3 kinase inhibition using an AKT 1 redistribution assay. Comb. Chem. High Throughput Screen. 9, 339–350 (2006).
Almholt, D.L. et al. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen. Assay Drug Dev. Technol. 2, 7–20 (2004).
Granas, C. et al. Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen. J. Biomol. Screen. 11, 423–434 (2006).
Rickardson, L., Wickstrom, M., Larsson, R. & Lovborg, H. Image-based screening for the identification of novel proteasome inhibitors. J. Biomol. Screen. 12, 203–210 (2007).
Online Mendelian Inheritance of Man (OMIM). (Johns Hopkins University and National Center for Biotechnology Information, National Library of Medicine, 2007). <http://www.ncbi.nlm.nih.gov/omim/>
Habashi, J.P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117–121 (2006).
Jarecki, J. et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14, 2003–2018 (2005).
Welch, E.M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91 (2007).
Bernier, V., Lagace, M., Bichet, D.G. & Bouvier, M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 15, 222–228 (2004).
Sazani, P. et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965–3974 (2001).
Zhang, X. et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 892–897 (2005).
Kenakin, T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat. Rev. Drug Discov. 2, 429–438 (2003).
Van Der Hee, R.M., Deurholt, T., Gerhardt, C.C. & De Groene, E.M. Comparison of 3 AT1 receptor binding assays: filtration assay, ScreenReady Target, and WGA Flashplate. J. Biomol. Screen. 10, 118–126 (2005).
Wu, X., Glickman, J.F., Bowen, B.R. & Sills, M.A. Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J. Biomol. Screen. 8, 381–392 (2003).
Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103, 11473–11478 (2006).
Burlingham, B. & Widlanski, T. An intuitive look at the relationship of Ki and IC50: a more general use for the Dixon plot. J. Chem. Educ. 80, 214–218 (2003).
Copeland, R.A. Mechanistic considerations in high-throughput screening. Anal. Biochem. 320, 1–12 (2003).
Leff, P. & Dougall, I.G. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci. 14, 110–112 (1993).
Wu, G., Yuan, Y. & Hodge, C.N. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J. Biomol. Screen. 8, 694–700 (2003).
Knight, S.M., Umezawa, N., Lee, H.S., Gellman, S.H. & Kay, B.K. A fluorescence polarization assay for the identification of inhibitors of the p53–DM2 protein-protein interaction. Anal. Biochem. 300, 230–236 (2002).
Kane, S.A. et al. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal. Biochem. 278, 29–38 (2000).
Zuck, P. et al. Ligand-receptor binding measured by laser-scanning imaging. Proc. Natl. Acad. Sci. USA 96, 11122–11127 (1999).
Zhang, R. et al. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Anal. Biochem. 331, 138–146 (2004).
Parks, D.J. et al. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15, 765–770 (2005).
Inglese, J. Engaging science and technology for drug development. Assay Drug Dev. Technol. 1, 1 (2002).
Lundholt, B.K., Heydorn, A., Bjorn, S.P. & Praestegaard, M. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. Assay Drug Dev. Technol. 4, 679–688 (2006).
Peppard, J. et al. Development of a high-throughput screening assay for inhibitors of aggrecan cleavage using luminescent oxygen channeling (AlphaScreen). J. Biomol. Screen. 8, 149–156 (2003).
DeForge, L.E. et al. Substrate capacity considerations in developing kinase assays. Assay Drug Dev. Technol. 2, 131–140 (2004).
Iyer, R., Barrese, A.A. III, Parakh, S., Parker, C.N. & Tripp, B.C. Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J. Biomol. Screen. 11, 782–791 (2006).
Comley, J. Assay Interference, a limiting factor in HTS? Drug Discov. World 4, 91–98 (2003).
Zheng, W. et al. Miniaturization of a hepatitis C virus RNA polymerase assay using a -102 degrees C cooled CCD camera-based imaging system. Anal. Biochem. 290, 214–220 (2001).
Rishton, G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 8, 86–96 (2003).
Swift, K., Anderson, S.N. & Matayoshi, E.D. in Advances in Fluorescence Sensing Technology V, Proceedings of SPIE - The International Society for Optical Engineering 4252 47–58 (2001).
Porcari, V., Magnoni, L., Terstappen, G.C. & Fecke, W. A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors. Assay Drug Dev. Technol. 3, 287–297 (2005).
Moger, J., Gribbon, P., Sewing, A. & Winlove, C.P. The application of fluorescence lifetime readouts in high-throughput screening. J. Biomol. Screen. 11, 765–772 (2006).
Feng, B.Y. et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385–2390 (2007).
Bakhtiarova, A. et al. Resveratrol inhibits firefly luciferase. Biochem. Biophys. Res. Commun. 351, 481–484 (2006).
Ullman, E.F. et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. USA 91, 5426–5430 (1994).
Issad, T., Blanquart, C. & Gonzalez-Yanes, C. The use of bioluminescence resonance energy transfer for the study of therapeutic targets: application to tyrosine kinase receptors. Expert Opin. Ther. Targets 11, 541–556 (2007).
Zlokarnik, G. et al. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279, 84–88 (1998).
Kumaraswamy, S. et al. Fluorescent-conjugated polymer superquenching facilitates highly sensitive detection of proteases. Proc. Natl. Acad. Sci. USA 101, 7511–7515 (2004).
Kiss, L. et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol. 1, 127–135 (2003).
Acknowledgements
We thank D. Leja and J. Fekces for illustrations. The authors are supported by the Molecular Libraries Initiative of the NIH Roadmap for Medical Research and the Intramural Research Program of the National Human Genome Research Institute, NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Inglese, J., Johnson, R., Simeonov, A. et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3, 466–479 (2007). https://doi.org/10.1038/nchembio.2007.17
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2007.17
This article is cited by
-
qHTSWaterfall: 3-dimensional visualization software for quantitative high-throughput screening (qHTS) data
Journal of Cheminformatics (2023)
-
Semi-quantitatively Predicting the Residence Time of Three Natural Products on Endothelin Receptor A by Peak Profiling Using the Receptor Functionalized Macroporous Silica Gel as Stationary Phase
Journal of Analysis and Testing (2023)
-
Selective optogenetic control of Gq signaling using human Neuropsin
Nature Communications (2022)
-
Light sheet fluorescence microscopy
Nature Reviews Methods Primers (2021)
-
Multiwell Raman plate reader for high-throughput biochemical screening
Scientific Reports (2021)